Tagged with RNA

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. pharmaboardroom · The bright future of…

USA Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan therapies in Europe, here we move to the world’s biggest biopharmaceutical market and R&D hub, shining the spotlight on five of the most important and innovative rare-disease start-ups in the USA.   The US…

Asia-Pacific The latest pharma news from the Asia-Pacific region, including upcoming IPOs for Prestige Biopharma and HH&L Acquisition; logistics challenges for COVID-19 vaccine distributors; and Moderna’s CMO-based vaccine manufacturing strategy in Asia.   Singapore-based Prestige Biopharma prepares for IPO on the Korea Exchange https://www.businesstimes.com.sg/garage/prestige-biopharma-eyes-at-least-18t-won-valuation-in-korean-ipo SINGAPORE-BASED Prestige Biopharma expects an implied market…

Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company.   We quickly recognized that the…

USA Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch ten or more products by 2025.   We have many programs currently in Phase III development. All these medicines are…

Rankings Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural mechanism which is present in living cells that selectively “turns off” specific gene’s expressions, thereby affecting the production of a specific protein that contributes to disease.…

Czech Republic The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical trials. However, a decline in the number of clinical trials in recent years means that Czech stakeholders are looking to…

Romania Cătălin Vicol introduces Biofarm, a leading Romanian pharma producer on the verge of significant international expansion. Vicol shares his insights on the potential of the Romanian consumer healthcare (CHC) market, which accounts for 95 percent of Biofarm’s activities, and discloses his ambition of becoming the number one CHC pharmaceutical producer…

Czech Republic Pavla Rozmarová, clinical research associate manager & regional OD for the Czech affiliate of German CRO Scope International, describes how the Czech clinical research landscape has evolved in the past few years and how Scope has moved to employ a younger generation to capitalize on the industry’s technological shift. Moreover,…

Italy Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare diseases.   We are very excited to put Chiesi’s decades of experience in drug development and dedication to patients to work to make a positive difference…

India Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia and New Zealand markets.   We see ourselves as a company that has great capabilities and is investing big time…